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Enhanced GABAergic actions 
resulting from the coapplication 
of the steroid 3α-hydroxy-5α-
pregnane-11,20-dione (alfaxalone) 
with propofol or diazepam
Lily Q. Cao1, Michael C. Montana1, Allison L. Germann1, Daniel J. Shin1, Sampurna Chakrabarti  1, 
Steven Mennerick2,4, Carla M. Yuede3, David F. Wozniak2,4, Alex S. Evers1,4 & Gustav Akk1,4
Many GABAergic drugs are in clinical use as anesthetics, sedatives, or anxiolytics. We have investigated 
the actions of the combinations of the neuroactive steroid 3α-hydroxy-5α-pregnane-11,20-dione 
(alfaxalone) with the intravenous anesthetic propofol or the benzodiazepine diazepam. The goal 
of the study was to determine whether coapplication of alfaxalone reduces the effective doses and 
concentrations of propofol and diazepam. Behavioral effects of alfaxalone, propofol, diazepam, and 
the combinations of the drugs were evaluated during a 30-min activity test in mice. Functional effects of 
the individual drugs and drug combinations were tested by measuring the decay times of spontaneous 
inhibitory postsynaptic currents in rat hippocampal neurons, and peak current responses from 
heterologously expressed concatemeric α1β2γ2L GABAA receptors. Co-administration of alfaxalone 
increased the sedative actions of propofol and diazepam in mice. The combination of alfaxalone with 
propofol or diazepam increased the decay times of sIPSCs and shifted the concentration-response 
relationships for GABA-activated receptors to lower transmitter concentrations. We infer that 
alfaxalone acts as a co-agonist to enhance the GABAergic effects of propofol and diazepam. We propose 
that co-administration of alfaxalone, and possibly other neuroactive steroids, can be employed to 
reduce dosage requirements for propofol and diazepam.
The γ-aminobutyric acid type A (GABAA) receptor is the principal inhibitory ionotropic transmitter-gated ion 
channel in the brain1. A number of GABAergic compounds are in clinical use as anesthetics, sedatives, anxiolyt-
ics, and/or anticonvulsants2,3. These include intravenous anesthetics, such as propofol, and benzodiazepines, such 
as diazepam. Propofol is used for induction and maintenance of general anesthesia of surgical patients as well as 
sedation of critically ill patients. Diazepam is first-line treatment for seizures, and is also used to treat anxiety 
and panic attacks. Both drugs are widely-used clinically but can have significant shortcomings due to undesired 
side effects. Propofol can cause hypotension and respiratory depression at plasma concentrations reached during 
anesthesia4,5. Diazepam, particularly at higher doses, results in anterograde amnesia and sedation6,7. Thus it could 
be advantageous to develop approaches to administer lower doses of the drugs while maintaining overall clinical 
efficacy.
One conceivable approach to reduce drug dosage without compromising the desired clinical effects is to 
combine the clinical agent with another GABAergic compound, such as a potentiating neuroactive steroid, that 
acts as a background agonist or a co-agonist in activating the GABAA receptor. A recent study showed that the 
neurosteroid 3α-hydroxy-5α-pregnan-20-one (allopregnanolone) augments the ability of propofol to reduce 
action potential firing and prolong inhibitory postsynaptic currents in neocortical neurons8. We have previously 
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shown that etomidate-mediated potentiation of the recombinant α1β2γ2L GABAA receptor is amplified in the 
presence of the neurosteroid 3α-hydroxy-5β-pregnan-20-one (pregnanolone). The potential clinical relevance 
of the effect was demonstrated in behavioral studies, which revealed left-shifted dose-response relationships for 
loss-of-righting by etomidate in mice and Xenopus tadpoles, in the presence of the neurosteroid9.
To further explore this phenomenon, and to determine how it manifests in various in vivo and in vitro exper-
imental assays, we investigated the behavioral and functional effects of co-administration of the synthetic neu-
roactive steroid 3α-hydroxy-5α-pregnane-11,20-dione (alfaxalone) with propofol or diazepam. We employed 
alfaxalone because of its low logP value and relatively fast washout10. We show that the combination of alfaxalone 
with propofol or diazepam enhances sedation in mice as assessed by quantifying lack of movement during a 
30-min activity test conducted immediately following drug administration. Animals injected with the combi-
nation of propofol and alfaxalone also demonstrated loss-of-righting in the majority of animals whereas admin-
istration of either drug alone was ineffective. Coapplication of alfaxalone with propofol or diazepam increased 
the decay times of spontaneous inhibitory postsynaptic currents (sIPSCs) in rat hippocampal neurons. In 
two-electrode voltage clamp recordings from heterologously expressed concatemeric α1β2γ2L GABAA recep-
tors, coapplication of alfaxalone with propofol or diazepam shifted the GABA concentration-response curves to 
lower transmitter concentrations in a manner consistent with energetic additivity. Overall, the data indicate that 
the GABAergic effects of propofol and diazepam can be amplified by the steroid alfaxalone.
Results
The effects of the steroid alfaxalone on propofol- or diazepam-induced sedation in mice. Time 
at rest (absence of movement) was recorded during a 30-min locomotor activity test to evaluate potential sed-
ative effects following intraperitoneal injections of alfaxalone (30 mg/kg), propofol (50 mg/kg), the combined 
drug treatment (propofol + alfaxalone) or normal saline. A repeated measures (rm) ANOVA on the time at 
rest data (Fig. 1A) revealed a significant drug effect, [F(3,41) = 7.27, p = 0.005) and drug × time interaction 
[F(15,205) = 4.16, p < 0.00005], indicating significant differences among some of the groups, although these 
differences varied across the test session. Subsequent simple main effects tests showed that the time at rest for 
the mice treated with propofol + alfaxalone was significantly greater (Bonferroni corrected for 5 comparisons) 
on average across post-injection time during the test session than those of the saline control [F(1,41) = 18.09, 
p = 0.0005], alfaxalone alone [F(1,41) = 8.39, p = 0.030], or propofol alone [F(1,41) = 13.64, p = 0.003], groups. 
Analyzing differences between groups as a function of post-injection time showed that the effect of the propo-
fol + alfaxalone treatment on time at rest occurred fairly rapidly but was not particularly long-lasting. Specifically, 
significantly increased rest times were observed in the propofol + alfaxalone treated mice by 5-min post-injec-
tion compared to levels displayed by each single drug treatment and saline control groups, and these differences 
remained significantly different up until and including the 20-min time block (see Fig. 1A for “p” values associ-
ated with the pair-wise comparisons for specific 5-min time blocks within each of these three contrasts). Lastly, 
our results also showed that each of the single drug-treated groups did not differ from those of the saline control 
mice across the post-injection time.
A similar analysis was conducted on mice injected (ip) with diazepam alone (4 mg/kg), alfaxalone alone 
(30 mg/kg), the combination of diazepam + alfaxalone, or normal saline (Fig. 1B). An rmANOVA performed on 
the time at rest data revealed a significant drug effect, [F(3,36) = 55.68, p < 0.00005] and drug × time interaction 
[F(15,180) = 3.24, p = 0.0004]. Simple main effects tests showed that the diazepam + alfaxalone group displayed 
significantly increased rest times compared to saline control [F(1,36) = 136.12, p < 0.00005], alfaxalone alone 
[F(1,36) = 113.36, p < 0.00005], or diazepam alone [F(1,36) = 54.33, p < 0.00005] treated mice on average across 
the time blocks. Our analyses on group performance as a function of post-injection time indicated that the effect 
of the diazepam + alfaxalone treatment on time at rest occurred fairly rapidly and was long-lasting. This was doc-
umented by increased rest times in the diazepam + alfaxalone treated mice by 5-min post-injection compared to 
levels displayed by each single drug treatment and saline control groups. These differences remained significantly 
greater throughout the entire 30-min test session (see Fig. 1B for specific “p” values associated with the pair-wise 
comparisons for the 5-min time blocks). In addition, the diazepam alone group had significantly increased rest 
times relative to the saline control mice [F(1,36) = 18.46, p = 0.0006] (Fig. 1B), with significant pair-wise compar-
isons being observed for the 5–25 post-injection time blocks (see Fig. 1B for the “p” values associated with these 
comparisons).
To provide additional perspective concerning the magnitudes of the behavioral effects resulting from the 
administration of propofol + alfaxalone or diazepam + alfaxalone, we compared the performance levels induced 
by these treatments with those resulting from the mathematical sums of the respective single drug applications. 
For this purpose, we computed the percent change in the mean times at rest for each of the individual and com-
bined drug treatments by normalizing them to the mean percentages observed in the saline-injected controls 
from each of the two studies. We then summed the percentages from each of the single drug treatments and 
plotted them, along with percentages derived for the co-administered groups, as a function of time across the 
test session. The data from the study involving the co-administration of propofol + alfaxalone (Fig. 2A) showed 
that, at the beginning of the test session, the percent time at rest above baseline was approximately 7 times 
higher for the co-administered group compared to that derived from adding together the percentages of the 
single applications of propofol and alfaxalone. These differences declined over the session such that the percent 
time at rest above baseline was slightly greater in the combined individual drug application group compared to 
those of the co-administered group by the last time interval. In contrast, the data from the co-administration 
of diazepam + alfaxalone study (Fig. 2B) revealed that the percent time at rest above baseline was higher in the 
co-administered group compared to those observed in the summed, single drug applications throughout the test 
session. The co-administered group exhibited increased percent times at rest that ranged from 8.3 times higher 
during the first 5-min interval to a low of a 1.4-fold difference at 15 min. Taken together, the percent change in the 
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time spent at rest above baseline for the co-administered drug groups supports the general idea that the sedating 
effects of the drug combinations exceeded the additive effects of the sum of the individual drug applications at 
least for some of the earlier post-injection time intervals.
The mice were also scored for loss-of-righting. A loss of the righting reflex was observed in 10/12 mice in the 
propofol + alfaxalone group, while it was not observed in any mice (0/11) from the other three groups treated with 
saline, propofol or alfaxalone. In the diazepam + alfaxalone group, loss-of-righting was observed in 2/10 mice. In 
saline- or alfaxalone-treated groups no mice (0/10) exhibited loss of righting whereas 1/10 mice treated with diaz-
epam alone demonstrated loss of the righting reflex. We note that there is some apparent discordance between 
the time at rest and the loss-of-righting data across the two drug studies. In the propofol + alfaxalone study, high 
levels of time at rest and loss-of-righting were both observed in the co-administered drug group. In contrast, in 
the diazepam + alfaxalone study, loss-of-righting was observed in only 20% of the mice in the co-administered 
drug group, although the mice in this group typically displayed high levels of time at rest throughout most of the 
test session. The latter finding was due to most mice in the co-administered group exhibiting a post-injection 
response of not moving for extended periods of time, although many of them did not roll over on their sides or 
backs and therefore were not scored as showing a loss-of-righting.
The effects of propofol, diazepam, and alfaxalone on the decay time courses of sIPSCs. We 
tested the effect of coapplication of alfaxalone with propofol or diazepam on the decay time course of sIPSCs. 
Under control conditions, i.e., in the absence of GABAergic modulators, the mean 100-to-25% decay time (τD) 
of sIPSCs from cultured rat hippocampal neurons was 41 ± 9 ms (mean ± S.D.; n = 17 cells). A sample averaged 
sIPSC is shown in Fig. 3.
The concentrations of alfaxalone were selected based on previous data11. Exposure to 10 nM alfaxalone pro-
duced no effect (τD = 42 ± 10 ms; n = 9 cells; p > 0.9) while the application of 300 nM alfaxalone increased the 
decay time to 85 ± 26 ms (n = 9; p < 0.001). Sample sIPSCs are shown in Fig. 3 and the data are summarized in 
Fig. 4A.
Figure 1. Effects of combining alfaxalone with propofol, or with diazepam on mouse behavior. (A) A 30-
min activity test was conducted immediately following i.p. injections of normal saline (20 Units), propofol 
(50 mg/kg), alfaxalone (30 mg/kg), or the combination of propofol (50 mg/kg) + alfaxalone (30 mg/kg), to 
determine drug effects on time at rest (absence of movement) as a function of post-injection time (5-min 
blocks) across the test session (means ± S.E.M.; n = 11–12 mice per treatment group). A repeated measures 
(rm) ANOVA revealed a significant drug effect (**p = 0.0005) and drug × time interaction (***p < 0.00005), 
with the propofol + alfaxalone mice exhibiting significantly increased time at rest compared to the single drug/
saline control groups on average across the test session. Significant between-groups comparisons are shown 
for these contrasts: saline vs. propofol + alfaxalone at 5, 10, 15 (*p < 0.003), and 20 (*p = 0.031) min post-
injection; alfaxalone vs. propofol + alfaxalone at 5, 10 (†p < 0.002), and 20 (†p = 0.038) min; and propofol vs. 
propofol + alfaxalone at 5, 10 (#p < 0.0002), and 15 and 20 (#p < 0.040) min. No significant differences were 
observed for the contrasts involving the saline vs. propofol or saline vs. alfaxalone groups. (B) A separate 
study was conducted on an independent cohort of naïve mice to examine the potential sedating drug effects 
following i.p. injections of normal saline (20 Units), diazepam (4 mg/kg), alfaxalone (30 mg/kg), or the 
combination of diazepam (4 mg/kg) + alfaxalone (30 mg/kg) on time at rest (n = 10 for each group). An 
rmANOVA yielded a significant drug effect (**p < 0.00005) and drug × time interaction (***p = 0.0004), 
with the diazepam + alfaxalone treated mice having significantly greater times at rest compared to the saline, 
alfaxalone, and diazepam groups on average across the session. Between-groups comparisons conducted 
within these contrasts showed robust differences between each of the single drug/saline control groups relative 
to the diazepam + alfaxalone treated mice for every post-injection time (5–30 min) interval (p < 0.0002; for 
the comparisons involving saline (*), alfaxalone (†), or diazepam (#), respectively). The diazepam group also 
had significantly increased rest times relative to the saline control mice, with pair-wise comparisons revealing 
significant differences at 10, 15, 20, and 25-min post-injection (††p < 0.003).
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Bath exposure to micromolar concentrations of propofol increased τD. In the presence of 1 μM or 3 μM propo-
fol, the mean decay times were 82 ± 22 ms (n = 7; p < 0.001) or 131 ± 7 ms (n = 4; p < 0.001), respectively. At 
lower concentrations of propofol tested (10–300 nM), the effects were not significantly different from the control 
value (Fig. 4B).
The propofol-induced increase of decay times was not affected by coapplication of 10 nM alfaxalone with 
propofol, i.e., at any tested propofol concentration the τD was not different in the absence and presence of 10 nM 
alfaxalone (Fig. 4B). In contrast, the combination of 300 nM alfaxalone with 100 nM to 1 μM propofol prolonged 
the decay time beyond that observed with either drug alone. At 100 and 300 nM propofol the effects of coappli-
cation with 300 nM alfaxalone can be described as supra-additive because exposure to propofol alone did not 
prolong τD. The results are summarized in Fig. 4B.
Exposure of the cells to 10–1000 nM diazepam increased the decay times of sIPSCs. The τD was 63 ± 13 (n = 6; 
p < 0.01 vs. control data), 65 ± 16 ms (n = 6; p < 0.01) or 87 ± 27 ms (n = 5; p < 0.001) with bath-applied 10, 100 
or 1000 nM diazepam. The application of 1–3 nM diazepam did not have a significant effect on the decay time 
course.
Coapplication of 10 nM alfaxalone did not modify diazepam-induced prolongation of τD at any tested con-
centration of diazepam (Fig. 4C). In the presence of the combination of 300 nM alfaxalone and 10 nM, 100 nM 
or 1 μM diazepam, the decay times were greater than in the presence of either drug alone. However, alfaxalone 
and diazepam alone at these concentrations had significant effects on the decay time. The calculated sums of 
individual effects were greater than the control-subtracted effects of the drug combinations. For the combina-
tion of 10 nM diazepam +300 nM alfaxalone, the control-subtracted τD was 119 ± 62 ms whereas the sum of 
control-subtracted effects of individual drugs was 67 ± 31 ms. Similarly, for the combinations of 100 nM or 1 μM 
diazepam +300 nM alfaxalone, the control-subtracted decay times were 123 ± 37 and 123 ± 35 ms, and the sums 
of individual drug effects were 69 ± 33 and 91 ± 39 ms, respectively. We used two-way ANOVA12 (but see13) to 
determine if the differences between the combined treatments and the sums of individual treatments were signifi-
cant. Significant interactions were found for alfaxalone and 10 nM diazepam [F(1,34) = 6.91; p < 0.013] or 100 nM 
diazepam [F(1,32) = 13.67; p < 0.001]. The interaction failed to reach statistical significance for 1 μM diazepam 
[F(1,31) = 4.00; p = 0.054].
The effects of alfaxalone on potentiation of recombinant concatemeric α1β2γ2L GABAA recep-
tors by propofol and diazepam. Alfaxalone, propofol and diazepam potentiate the αβγ GABAA receptor 
activated by low concentrations of the transmitter14–17. We examined the effects of the drugs, individually and in 
combination, on peak responses from concatemeric α1β2γ2L GABAA receptors activated by a low concentration 
of GABA. Raw current responses were converted to units of open probability, as described in Methods, that were 
analyzed in the framework of the co-agonist concerted transition model18,19.
Fitting Equation (1) to pooled estimated open probability (Po) data obtained in the presence of 1–1000 μM 
GABA yielded a KGABA (equilibrium dissociation constant of the closed receptor for GABA) of 35.3 ± 6.6 μM 
(best-fit parameter ± standard error of the fit) and a cGABA (measure of gating efficacy for GABA; see Methods) 
of 0.0045 ± 0.0004. Analysis of data from receptors activated by 10–2000 μM propofol gave a KPRO (equilibrium 
Figure 2. Comparison of the behavioral effects of from the co-administration of drugs with the sum of 
effects of individual drugs. (A) The graph compares the performance levels induced by the co-administration 
of propofol + alfaxalone to that resulting from the mathematical sums of the single drug applications. The 
magnitude of change in the mean percent times at rest above baseline for the co-administration of the drugs was 
greater early on in the test session, being approximately 7 times higher during the first time interval compared 
to that derived from adding together the percentages of the single applications of propofol and alfaxalone. These 
differences declined over the session such that the percentages from the two conditions were roughly equivalent 
by the end of the test session. (B) The graph compares the performance levels induced by the co-administration 
of diazepam + alfaxalone to that resulting from the mathematical sums of the single drug applications. The 
percent time at rest above baseline was consistently higher throughout the test session in the co-administered 
group compared to the percent change observed in the summed, single drug applications. The degree of change 
in the percent times at rest above baseline ranged from being 8.3 to 1.4 times higher in the co-administered 
drug group.
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dissociation constant of the closed receptor for propofol) of 44.8 ± 8.9 μM and a cPRO of 0.04 ± 0.002. The data and 
the fits are shown in Fig. 5A.
Alfaxalone and diazepam exhibit low efficacy as direct activators of the GABAA receptor. This makes direct 
determination of the binding and gating parameters in the wild-type receptor technically unfeasible. To deter-
mine the binding and gating properties for alfaxalone and diazepam, we measured the potentiation properties 
of these two drugs coapplied with a low concentration (2 μM) of GABA. In this experiment, GABA acts as a 
co-agonist that facilitates channel opening and unveils the functional effect of a weak activator.
The data showing potentiation of GABA-activated receptors by alfaxalone, diazepam, or propofol are given in 
Fig. 5B. Using Equation (1), we estimate that KALF (equilibrium dissociation constant of the closed receptor for 
alfaxalone) is 2.9 ± 0.5 μM and cALF is 0.11 ± 0.006. For diazepam, we estimate that KDZP (equilibrium dissociation 
constant of the closed receptor for diazepam) is 0.17 ± 0.02 μM and cDZP is 0.18 ± 0.004. We also recorded poten-
tiation of GABA-activated receptors by propofol, which yielded a KPRO of 52.8 ± 25.7 μM and a cPRO of 0.03 ± 0.01. 
These values are similar to the estimates obtained from direct activation by propofol (44.8 μM and 0.04, respec-
tively), indicating that the actions of GABA and propofol are energetically additive and independent. The data 
indicate that the potentiating actions of propofol are not due to the drug modifying the affinity of the receptor to 
the transmitter. Instead, propofol acts as a co-agonist, modifying the open-closed equilibrium. This finding is in 
agreement with previous reports20,21. The activation properties of the receptor in the presence of GABA, propofol, 
alfaxalone, and diazepam are summarized in Table 1.
The binding of GABA (to two sites) contributes −6.38 kcal/mol to stabilization of the open state, shifting the 
open-closed equilibrium by 50,000-fold toward the open state. Propofol contributes −5.70 kcal/mol of stabiliza-
tion energy. Alfaxalone and diazepam contribute −2.59 kcal/mol and −1.01 kcal/mol, respectively. The relatively 
weak potentiating effect observed in the presence of diazepam (Fig. 5B) is, in part, due to the receptor containing 
a single high-affinity binding site for diazepam.
Figure 3. Effects of alfaxalone, propofol and diazepam on synaptic currents. Sample averaged sIPSCs recorded 
under control conditions, or in the presence of 10 nM alfaxalone (ALF), 300 nM alfaxalone, 10 nM propofol 
(PRO), 1 μM propofol, 3 nM diazepam (DZP), 1 μM diazepam, or the combinations of propofol + alfaxalone or 
diazepam + alfaxalone. The drugs were added to the bath at least 10 min before recordings. All traces are from 
separate cells.
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We next determined whether the estimated affinity and efficacy values for alfaxalone and diazepam can be 
used to accurately predict shifts in GABA-activation curves in the presence of a fixed concentration of a modu-
lator. For that, we measured GABA concentration-response relationships in the presence of 1 μM alfaxalone or 
1 μM diazepam (Fig. 5C). The data were analyzed using Equation (1) where the value of L was modified to reflect 
background activity due to direct gating by the modulator. Since direct gating by 1 μM alfaxalone or diazepam 
could not be reliably measured (Po < 0.001), the level of activity (Po,background) in the presence of alfaxalone or 
diazepam was calculated using Equation (1) and the K and c values for alfaxalone and diazepam determined in 
the presence of GABA (Fig. 5B).
The estimates for KGABA and cGABA obtained in the presence of 1 μM alfaxalone were 39.5 ± 17.5 μM and 
0.0046 ± 0.0016, and in the presence of 1 μM diazepam 40.8 ± 5.8 μM and 0.0047 ± 0.0005. These values are 
Figure 4. Summary of the effects of alfaxalone, propofol and diazepam on synaptic currents. (A) Summary 
of the decay time courses of sIPSCs recorded under control conditions or in the presence of 10 nM or 300 nM 
alfaxalone. The graph shows data from each cell tested (open circles) and mean ± S.D. for the experimental 
condition (filled circles and error bars). (B) Summary of the decay time courses of sIPSCs recorded in the 
presence of propofol with or without alfaxalone. The open symbols show data from each cell tested, and the 
filled symbols and error bars show mean ± S.D. Due to saturation at lower propofol concentrations, 3 μM 
propofol was not tested in the presence of 300 nM alfaxalone. Statistical analysis was done by comparing the 
decay times for 10 nM-3 μM propofol to control, using ANOVA with Dunnett’s correction. For combinations 
of propofol and alfaxalone, the top symbol applies to comparison of propofol + alfaxalone with alfaxalone 
alone. The bottom symbol applies to comparison of propofol + alfaxalone with propofol alone. (C) Summary 
of the decay time courses of sIPSCs recorded in the presence of diazepam with or without alfaxalone. The open 
symbols show data from each cell tested, and the filled symbols and error bars show mean ± S.D. Statistical 
analysis was done by comparing the decay times for 1 nM-1 μM diazepam to control. For combinations of 
diazepam and alfaxalone and, the top symbol applies to comparison of diazepam + alfaxalone with alfaxalone 
alone. The bottom symbol applies to comparison of diazepam + alfaxalone with diazepam alone. In (B) and 
(C), the solid line shows the decay time under control conditions (no modulators). The dashed line shows the 
decay time in the presence of 10 nM alfaxalone. The dotted line shows the decay time in the presence of 300 nM 
alfaxalone. The number of cells was 3–17 for control, drug, or drug combinations. #not significant; *p < 0.05; 
**p < 0.01; ***p < 0.001.
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Figure 5. Activation and modulation of concatemeric α1β2γ2L GABAA receptors. (A) Direct activation of the 
receptor by GABA, propofol (PRO), or alfaxalone (ALF). The ordinate shows the estimated open probability (Po). 
The curves for GABA and propofol were generated by fitting Equation (1) to experimental data. Direct activation 
by alfaxalone produced very small currents (<100 nA at 30 μM). The predicted activation curve for alfaxalone was 
generated using KALF and cALF values determined in (B). (B) Potentiation of GABA-activated receptors by propofol, 
alfaxalone, or diazepam (DZP). The solid curves were generated by fitting Equation (1) to the data. L was held at 
(1 − Po,2 μM GABA)/Po,2 μM GABA. The dashed line shows the predicted propofol-potentiation curve using KPRO and cPRO 
values from (A). (C) Activation by GABA in the presence of 1 μM diazepam, 1 μM alfaxalone or the combination 
of diazepam + alfaxalone. The curves for single modulators were generated by fitting Equation (1) to the data. L 
was held at at (1 − Po,1 μM ALF)/Po,1 μM ALF or at (1 − Po,1 μM DZP)/Po,1 μM DZP . The open probability for receptors activated 
by 1 μM alfaxalone or 1 μM diazepam was calculated from the KALF and cALF, or KDZP and cDZP values estimated in 
(B). The simulated curve for the combination of diazepam + alfaxalone was calculated using Equation (1) and the 
KGABA and cGABA values from (A), and KALF, cALF, KDZP and cDZP values from (B). (D) Activation by GABA in the 
presence of 10 μM propofol, 1 μM alfaxalone or the combination of propofol + alfaxalone. The curve for propofol 
(green dashed line) is based on data from a previous report45. The data for alfaxalone are reproduced from panel C. 
The simulated curve for the combination of propofol + alfaxalone was calculated using Equation (1) and the KGABA, 
cGABA, KPRO and cPRO values from (A), and KALF and cALF values from (B). In (C) and (D), the black dotted lines 
show the GABA concentration-response relationship in the absence of modulators (from A). In all panels the data 
points show mean ± S.D. from at least five cells.
Agonist Background agonist L K (μM) c
GABA None 9000 35.3 ± 6.6 0.0045 ± 0.0004
Propofol None 9000 44.8 ± 8.9 0.04 ± 0.002
Alfaxalone 2 μM GABA 66 ± 36 2.9 ± 0.5 0.11 ± 0.006
Diazepam 2 μM GABA 37 ± 16 0.17 ± 0.02 0.18 ± 0.004
Table 1. Summary of activation properties. The K (equilibrium dissociation constant of the closed receptor) 
and c (ratio of the equilibrium dissociation constant of the closed receptor to that of the open receptor) values 
were estimated by fitting Equation (1) to the concentration-response data (Fig. 5). The number of binding sites 
was held at 2 for GABA, 3 for propofol, 2 for alfaxalone, and 1 for diazepam (see Methods). The value for L was 
held at 9000 in the absence of a background agonist or at the value calculated from estimated open probability 
of the background agonist (2 μM GABA) as (1 − Po,background)/Po,background.
www.nature.com/scientificreports/
8ScIeNTIFIc REPORtS |  (2018) 8:10341  | DOI:10.1038/s41598-018-28754-7
remarkably similar to the KGABA and cGABA estimates obtained in experiments conducted in the absence of mod-
ulators (35.3 μM for KGABA and 0.0045 for cGABA) thereby indicating that the effects of alfaxalone and diazepam 
on GABA-activated receptors can be accounted for by independent and additive energetic contributions to the 
open-closed equilibrium. We attempted fitting the curves to a full co-agonist model18 with no constraints on K 
and c for either agonist. However, the fits did not converge, possibly due to poorly defined responses at low GABA 
concentrations.
Finally, we examined the effect of the combinations of 1 μM diazepam +1 μM alfaxalone and 10 μM propofol 
+1 μM alfaxalone on the GABA concentration-response relationship. These drug combinations tested the ener-
getic independence and additivity of the agonists in the three-drug mixtures of GABA + diazepam + alfaxalone 
and GABA + propofol + alfaxalone. The predicted Po curves (Fig. 5C,D), generated assuming that each agonist 
independently and energetically additively contributed to channel opening, are in good agreement with the 
experimental data points.
Overall, the data indicate that in the agonist combinations of GABA ± diazepam ± alfaxalone and 
GABA ± propofol ± alfaxalone, each drug acts independently and energetically additively to stabilize the open 
state of the concatemeric α1β2γ2L GABAA receptor. In the framework of the state function of the co-agonist 
model (Equation 1), each drug in these agonist combinations alters the value of L with no effect on the affinity 
(K) or efficacy (c) of the others. We note that energetic additivity manifests as apparent synergy because, at least at 
low drug concentrations, the response to the drug combination is greater than the sum of individual responses22.
Discussion
Propofol, diazepam and alfaxalone potentiate transmitter-elicited current responses from the GABAA recep-
tor14–17. Additionally, propofol is an efficacious direct activator of the receptor20,21,23. The GABAergic activity 
of these compounds underlies their sedative and anesthetic effects24–26. The goal of this study was to establish 
whether coapplication of the neuroactive steroid alfaxalone modifies the actions of propofol and diazepam in 
different assays aimed at measuring GABAergic inhibitory activity. Specifically, we determined the effects of com-
bining alfaxalone with propofol or diazepam on sedation-like behavior in mice by analyzing time spent at rest 
and loss-of-righting during an activity test conducted over the 30-min post-injection period. The doses of the 
drugs were selected to elicit minimal effect when administered alone. The behavioral endpoints were correlated 
with the effects of combining alfaxalone with propofol or diazepam on the decay time properties of sIPSCs from 
hippocampal neurons, and on peak current responses from recombinant concatemeric synaptic-type α1β2γ2L 
GABAA receptors.
We report that co-administration of alfaxalone with either propofol or diazepam in mice greatly amplifies 
effects on sedation-like behavior. Intraperitoneal injections of the combinations of propofol + alfaxalone and 
diazepam + alfaxalone resulted in significantly enhanced levels of time spent at rest, compared to mice exposed 
to a single drug or saline-control treatments. Analysis of behavioral performance over the post-injection test 
session showed that both combinatorial drug treatments involving alfaxalone produced fast-acting changes in 
sedation-like behavior such that they each increased time at rest by the first 5-min time block compared to the 
single drug treatment or saline control groups. Analyzing behavioral responses over the post-injection time also 
revealed that the diazepam + alfaxalone treatment produced robust increases in rest times throughout the entire 
30-min session relative to the single drug/saline groups, while the propofol + alfaxalone administration produced 
a shorter period of discernible effects, which were limited to the first 20 min post-injection.
Diazepam is often used as an anxiolytic whereas sedation is an undesired side effect. The data, as evaluated by 
the time at rest, show that co-administration of diazepam and alfaxalone increases the sedative effect of diaze-
pam alone. Our study was not designed to test the anxiolytic effects of the drugs and drug combinations, and the 
potential clinical usefulness of diazepam + alfaxalone remains to be determined in future studies.
Co-administration of propofol and alfaxalone resulted in loss-of-righting in 10/12 animals whereas none 
of the animals administered either drug alone or saline experienced loss-of-righting. At the doses selected the 
combination of diazepam + alfaxalone resulted in loss-of-righting in only 2/10 mice. The difference in the effects 
of propofol vs. diazepam when administered in combination with alfaxalone in producing loss-of-righting may 
be attributable to the differences in GABAA receptor subunit selectivity of the drugs, and the mediation of cer-
tain sedation-related behaviors by particular subtypes of the receptor. Benzodiazepines, such as diazepam, are 
selective for GABAA receptors containing a γ subunit27 which are predominantly localized to synapses28. Propofol 
and neuroactive steroids modulate all heteromeric GABAA receptor subtypes, including δ subunit-containing 
extrasynaptic receptors, and are effective anesthetics. A low dose of alfaxalone can only enhance the actions of 
diazepam at receptor subtypes that are modulated by benzodiazepines and can thus enhance diazepam’s anxio-
lytic/sedative effects. In contrast, alfaxalone can enhance the actions of propofol at all GABAA receptor subtypes 
and thus enhances both its sedative and anesthetic effects.
The effects of combinations of alfaxalone with propofol on sIPSCs were supra-additive at several concen-
tration combinations where propofol applied alone had no effect on τD but significantly enhanced the ability of 
alfaxalone to modulate the decay time course. For diazepam + alfaxalone, the effects on τD were greater for the 
combination than for either drug applied alone, however, each drug applied alone produced a significant effect.
In two-electrode voltage clamp recordings, we employed quantitative analysis based on the co-agonist con-
certed transition model18 to determine the binding and gating properties for GABA, propofol, alfaxalone, and 
diazepam. The major finding is that the effects of the drugs can be accounted for by independent and addi-
tive changes in free energy. The functional effects of the combinations of GABA ± propofol ± alfaxalone and 
GABA ± diazepam ± alfaxalone could be accurately predicted from the individual effects of the drugs on the 
open-closed equilibrium assuming independent energetic contributions. We note that the observed energetic 
additivity predicts that the drug combinations exhibit synergy in isobolographic analysis22.
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The effective concentrations of the GABAergic modulators were similar in neuronal and oocyte preparations. 
A 2-3-fold prolongation (statistically significant) of the decay times of sIPSCs was observed in the presence of 
300 nM alfaxalone, 1 μM propofol or 10–100 nM diazepam. Inhibitory synaptic events in hippocampal cultures 
are mediated by GABAA receptors comprising α1, α2, β2, β3 and γ2 subunits29,30. In two-electrode voltage clamp 
recordings on concatemeric α1β2γ2L receptors, these concentrations elicited an approximately 2-fold increase 
in the peak response.
This study adds to the growing body of evidence demonstrating enhanced functional effects in electrophys-
iological and behavioral assays resulting from exposure to combinations of GABAergic modulators. Anesthetic 
steroids potentiate the actions of the intravenous anesthetics propofol and etomidate in electrophysiologi-
cal8 and behavioral assays9,31. Similarly, coapplication of neuroactive steroids enhances the anxiolytic effect 
of the benzodiazepine triazolam32,33 and the anticonvulsant potency of diazepam against seizures induced by 
pentylenetetrazol34.
In summary, our results show that the GABAergic effects of propofol and diazepam are enhanced in the 
presence of alfaxalone. Quantitative analysis of electrophysiological responses from heterologously-expressed 
receptors shows that the effects of drug combinations are accounted for by independent and additive energetic 
effects of the modulators, which predict curvilinear isoboles of additivity that are typically associated with syn-
ergy. Examination of the properties of sIPSCs indicates that combination of alfaxalone with subthreshold concen-
trations of propofol elicits supra-additive effects on the decay times of sIPSCs. Behavioral tests in mice show that 
the actions of propofol and diazepam are amplified in the presence of alfaxalone. These are potentially valuable 
findings. In cases where the two drugs in a pair are linked to different off-target effects, the combinations of drugs 
enable reduction of the dose of each drug and, while retaining an intended GABAergic output, may lower the 
off-target side effects.
Methods
Behavioral assays. Behavioral assays were conducted on 7-week old male Swiss-Webster mice. The experi-
ments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals of the National 
Institutes of Health. The protocol for use of mice was approved by the Animal Studies Committee of Washington 
University in St. Louis (Approval Nos 20150065; 20150076).
A total of 85 mice purchased from Taconic (Hudson, NY) were acclimated to the new housing conditions for 
at least 1 week prior to behavioral testing. All mice were housed in a 12/12-light/dark schedule with ad libitum 
access to food and water. Initial experiments were conducted with alfaxalone, propofol, and diazepam to establish 
doses that appeared to produce sedation based on the results of ambulatory activity (data not shown) and subse-
quent injections were performed using a presumed subsedative dose of each drug.
For experiments testing the combinatorial effects of alfaxalone and propofol, mice were injected intraperitone-
ally either with 20 Units of normal saline, 50 mg/kg propofol, 30 mg/kg alfaxalone, or both 50 mg/kg propofol and 
30 mg/kg alfaxalone (n = 11–12 mice per group). Immediately following injection mice were placed individually 
into translucent (47.6 × 25.4 × 20.6 cm) chambers and sedation-related behavior was quantified over a 30-min 
period using computerized photobeam instrumentation and standard algorithms as previously described35,36. 
The dependent variable for characterizing the sedative effects of drug treatments was time spent at rest, i.e., lack 
of movement. This was defined by an absence of a change in the status of any floor-level, photocell pairs (either 
newly cleared or blocked) along the x- and y-axes for at least a 2-s period. No baseline behavioral measures were 
collected to minimize possible “floor effects” resulting from decreased motor activity accruing from habituation 
to the testing environment, and thus help increase sensitivity for detecting sedative drug effects. The combinato-
rial effects of alfaxalone and diazepam were evaluated in the same manner except that mice were injected either 
with normal saline, 4 mg/kg diazepam, 30 mg/kg alfaxalone, or both 4 mg/kg diazepam and 30 mg/kg alfaxalone 
(n = 10 per group). The behavioral experiments were conducted within a 3-hr window to minimize changes in 
baseline activity associated with circadian rhythm.
Animals were also scored for the loss of the righting reflex during activity testing, which was recorded when 
a mouse spontaneously assumed a supine or prone position for greater than 30 seconds. This criterion avoided 
spurious beam breaks that would have occurred from an experimenter placing a mouse on its back and recording 
righting time when a mouse assumed an upright posture on all 4 limbs.
A repeated measures (rm) ANOVA model (SYSTAT 12, Systat Software, Inc., San Jose, CA), containing one 
between-subjects variable (drug) and one within-subjects variable (time post-injection) was used to analyze the 
time at rest data. Simple main effects tests were conducted after the rmANOVA to better understand the nature of 
drug × time interactions. The Huynh-Feldt (H-F) adjustment of alpha levels was utilized for all within-subjects 
effects containing more than two levels in order to help protect against violations of the sphericity/compound 
symmetry assumptions underlying this ANOVA model. General normality of the data was assessed by conduct-
ing the Shapiro-Wilk test on the times at rest summed across the activity session for the propofol + alfaxalone 
and diazepam + alfaxalone experiments. Results from this analysis did not reveal any significant departures from 
normality. Bonferroni adjusted “p” values are presented and were computed by multiplying uncorrected “p” val-
ues by the number of comparisons that were conducted for a given analysis. Probability values of p = 0.0000 are 
listed as p < 0.00005.
Hippocampal neurons, recordings and analysis of sIPSCs. Cultures of hippocampal neurons were 
prepared from rat brains as described previously11,37. The experiments were conducted in accordance with the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol for use of rats 
was approved by the Animal Studies Committee of Washington University in St. Louis (Approval No. 2015019).
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Synaptic currents were recorded from neurons cultured for 9–14 days. Coverslips with cells were transferred 
to a 60 mm dish containing 5 ml of bath solution. The bath solution contained (in mM): 140 NaCl, 5 KCl, 1 
MgCl2, 2 CaCl2, 10 D-glucose, 10 HEPES (pH adjusted to 7.4 with NaOH). In some cases, 5 µM CNQX and 25 µM 
DL-APV were added to bath to block glutamate receptor activity. In other cases, sIPSCs were distinguished from 
sEPSCs by difference in decay properties38.
Drugs (propofol, diazepam, and/or alfaxalone) were added to the bath at the indicated concentrations at least 
10 min before recording39. Each coverslip with neurons was exposed to a single drug or drug combination, to 
avoid technical artifacts due to incomplete washout of these lipophilic compounds from the cells. Control record-
ings (not shown) indicate that the sIPSCs are abolished by bath exposure to bicuculline and picrotoxin.
The pipette solution contained (in mM): 140 CsCl, 4 NaCl, 4 MgCl2, 0.5 CaCl2, 5 EGTA, 10 HEPES (pH 
adjusted to 7.4 with CsOH). Neurons were clamped at −70 mV. Pipette resistance was 4–5 MΩ. Series resistance 
was compensated to 75–85% in most recordings. All experiments were done at room temperature.
Currents were amplified with an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA), low-pass 
filtered at 1 kHz and digitized with a Digidata 1322 A interface (Molecular Devices) at 5 kHz. The detection 
and analysis of synaptic currents were conducted using pClamp 10 software (Molecular Devices) as described 
previously11.
The decay time courses of sIPSCs were characterized by determining the 100-to-25% decay time. We used this 
parameter rather than fitting the decay time course to sums of exponentials because of variability in the numbers 
of exponentials required for adequate fit in the presence of high concentrations of steroid and propofol. The data 
are expressed as mean ± S.D. (number of cells). The statistical analysis on decay times of sIPSCs was conducted 
using ANOVA with Dunnett’s correction (Stata/IC 12.1, StataCorp, College Station, TX).
Expression of recombinant GABAA receptors and two-electrode voltage-clamp recordings from 
Xenopus oocytes. Oocytes from Xenopus laevis (purchased from Xenopus 1, Dexter, MI) were used as the 
expression system for recombinant GABAA receptors. Oocyte harvest and animal handling were carried out in 
accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The 
protocol for use of frogs was approved by the Animal Studies Committee of Washington University in St. Louis 
(Approval No. 20170071).
Electrophysiological recordings were conducted on rat GABAA receptors consisting of β2-α1-γ2L and β2-α1 
concatemeric constructs, which have been shown to assemble as βαγβα (counterclockwise, top view)40. The 
generation and functional characterization of the concatemeric receptors have been reported previously41. The 
cDNAs in the pcDNA3 expression vector were linearized by digestion with Xba I (NEB Labs, Ipswich, MA). 
The cRNAs were produced using mMessage mMachine (Ambion, Austin, TX). Oocytes were injected with a 
total of 18 ng of cRNA in nuclease-free water (final volume 32 nl) and incubated in ND96 with supplements 
(96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM HEPES, and the supplements 2.5 mM Na pyruvate, 
100 U/ml penicillin, 100 μg/ml streptomycin, 50 μg/ml gentamycin; adjusted to pH 7.4 with NaOH) at 16 °C. 
Electrophysiological recordings were conducted during the next 2–3 days.
Recordings were conducted using standard two-electrode voltage clamp. The oocytes were clamped at 
−60 mV. The chamber (RC-1Z, Warner Instruments, Hamden, CT) was perfused with bath (ND96) or bath con-
taining the drugs at approximately 7 ml/min. The current responses were amplified with an Axoclamp 900 A 
amplifier (Molecular Devices, Sunnyvale, CA), filtered at 10 Hz, and digitized with a Digidata 1320 digitizer 
(Molecular Devices) at a 50 Hz sampling rate. The traces were subsequently analyzed with Clampfit (Molecular 
Devices) to determine the peak amplitude of the current response.
Receptor activity was analyzed in the co-agonist concerted transition model framework18,42. Raw current 
amplitudes were converted to units of open probability (Po)43,44. To that end, the current responses from each 
cell were compared to the reference response to 3 mM GABA + 50 μM propofol, that was considered to generate 
a response with a Po indistinguishable from 121,45. For example, exposure to saturating GABA produced a peak 
response that was 86 ± 8% (n = 9 cells) of the response to 3 mM GABA + 50 μM propofol. Accordingly, the max-
imal Po for GABA was estimated at 0.86 ± 0.08. This is similar to previous estimates of maximal Po for GABA in 
the ternary αβγ receptor21,46,47. The level of activity in the absence of any GABAergic drugs (Po = 0.0001122) was 
excluded in these calculations.















where K is the closed receptor equilibrium dissociation constant for the drug (GABA, propofol, alfaxalone, or 
diazepam), c is a measure of receptor gating efficacy expressed as the ratio of the equilibrium dissociation con-
stant of the open receptor to that of the closed receptor, and N is the number of binding sites for the agonist 
(constrained to 2 for GABA49, 3 for propofol21, 2 for alfaxalone50, and 1 for diazepam51). Stabilization energy 
provided by a drug was calculated as NRT × ln(c), where RT is the multiplication product of the gas constant and 
thermodynamic temperature, and other terms are as described above.
The parameter L reflects unliganded or background activity from the receptor. In the absence of any 
GABAergic agonists, it was constrained to 900021,22. In experiments where a low concentration of one GABAergic 
drug, i.e., a background drug, was coapplied with a range of concentrations of a second GABAergic agonist, L 
was calculated as (1 − Po,background)/Po,background, where Po,background is the open probability of the response to the 
background drug. In a standard potentiation experiment, where several concentrations of a potentiator (propofol, 
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alfaxalone or diazepam) were coapplied with a fixed low concentration of GABA, the response to GABA alone 
comprised the background response. Since exposure to 1 μM alfaxalone or 1 μM diazepam did not produce robust 
current responses, the Po,background for alfaxalone and diazepam were calculated using Equation (1) and the K and 
c values estimated for each drug in the presence of low GABA. Curve-fitting was carried out using Origin v. 7.5 
(OriginLab Corp., Northampton, MA).
Materials. The salts used in buffers, alfaxalone, diazepam, CNQX and DL-APV used in electrophysiological 
experiments were bought from Sigma-Aldrich (St. Louis, MO). Propofol was purchased from MP Biomedicals 
(Solon, OH). Stock solution of alfaxalone was made in DMSO at 10 mM and stored at room temperature. Stock 
solution of propofol was made in DMSO at 200 mM and stored at room temperature. For electrophysiological 
recordings, stock solution of diazepam was made in ND96 at 30 μM and stored at −20 °C. Dilutions to lower 
concentrations were made from that solution. The highest final concentration of DMSO was 0.3% (v/v). This 
concentration of DMSO has been shown to be without effect on currents from recombinant α1β2γ2L GABAA 
receptors or GABAA receptor-mediated synaptic currents52,53.
Pharmaceutical grade reagents were used in all behavioral experiments. Propofol (10 mg/ml, Hospira, Inc., 
San Jose, CA), alfaxalone (10 mg/ml, Jurox, Inc., Kansas City, MO), diazepam (5 mg/ml, Hospira, Inc.), combi-
nations of either propofol and alfaxalone, or diazepam and alfaxalone, or sterile normal saline (20 Units) were 
injected intraperitoneally using U-100 insulin syringes. Diazepam was diluted to 0.5 mg/ml with normal saline 
prior to injection.
Data availability. The datasets generated and/or analyzed during the current study are available from the 
corresponding author on reasonable request.
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